2024-09-02 - Analysis Report
## Stock Analysis Report for ABBV (AbbVie Inc.)

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company focused on developing and marketing innovative therapies in various areas, including immunology, oncology, neuroscience, and eye care. 

**Performance Analysis:**

**1. Return Performance:**
  * **Cumulative Return:** 106.38%
  * **S&P 500 (VOO) Cumulative Return:** 89.66%
  * **Performance Difference:** 16.72%
  * **Relative Divergence:** 65.53% (This means that ABBV's performance is currently at the 65.53% percentile of its historical performance relative to the S&P 500.)

**2. Recent Price Movements:**
  * **Closing Price:** 196.31
  * **5-day Moving Average:** 196.05
  * **20-day Moving Average:** 193.17
  * **60-day Moving Average:** 179.48

**3. Technical Indicators:**
  * **RSI:** 74.27 (High RSI suggests the stock is in overbought territory)
  * **PPO:** -0.36 (Negative PPO indicates a potential downtrend)
  * **Delta_Previous_Relative_Divergence:** -3.27 (Negative indicates a recent short-term decline in relative performance)
  * **Expected Return:** 16.29% (This is the maximum expected return over 5 years based on the current investment amount.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The most recent earnings report for the quarter ending July 25th, 2024, showed an EPS of 2.65, surpassing the expected EPS of 2.57. AbbVie's consistent performance has exceeded expectations in recent quarters.

**5. Summary and Analysis:**

* ABBV has outperformed the S&P 500 in terms of cumulative return, but its recent performance has shown some signs of weakness.
* The RSI suggests that the stock is overbought, and the negative PPO and Delta_Previous_Relative_Divergence indicate a potential short-term downtrend.
* However, AbbVie's consistent earnings performance exceeding expectations signals strong fundamentals. 
* The high expected return reflects the market's optimistic outlook on AbbVie's future prospects.

**Conclusion:** While the stock might be in an overbought territory, AbbVie's strong fundamentals and solid recent earnings performance support a potentially positive long-term outlook. 

**Disclaimer:** This report is for informational purposes only and should not be considered as investment advice. Any investment decisions should be made after consulting with a qualified financial advisor.